![](/wp-content/uploads/2018/10/wTGxMfc0TvO5zttwrjI8.png)
$599
Dasiglucagon Ph3 Meets Primary and Secondary Endpoints
Zealand Pharma announced positive topline results and held a subsequent investor call to discuss data from its Ph3 pivotal dasiglucagon hypoglycemia rescue trial. Below, FENIX provides an overview of the results and potential impact on the glucagon rescue market.